Synergistic protection of MLC 1 against cardiac ischemia/reperfusion- induced degradation: A novel therapeutic concept for the future

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 389-398

  Cadete, Virgilio J J ^a   Arcand, Steven A ^a   Lin, Han Bin ^a   Sawicki, Grzegorz ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; BATIMASTAT; CONTRACTILE PROTEIN; DOXYCYCLINE; GELATINASE A; GELATINASE B; ILOMASTAT; MARIMASTAT; MLC1 PROTEIN; PD 166793; TETRACYCLINE; UNCLASSIFIED DRUG;

CONFORMATIONAL TRANSITION; DRUG POTENTIATION; ENERGY YIELD; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HEART; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHORYLATION; PROTEOLYSIS; REACTIVE OXYGEN SPECIES;

EID: 84875157276     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.19     Document Type: Review

References (93)

1. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (9), e82-e292 (2004).
2. Cadete VJ, Sawicka J, Jaswal JS et al. Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS J. 279(13), 2444-2454 (2012).
3. Doroszko A, Polewicz D, Cadete VJ et al. Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction. Shock 34(6), 592-600 (2010).
4. Doroszko A, Polewicz D, Sawicka J et al. Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2. Basic Res. Cardiol. 104(6), 669-679 (2009).
5. Arrell DK, Neverova I, Fraser H, Marban E, Van Eyk JE. Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1. Circ. Res. 89(6), 480-487 (2001).
6. Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98(1), 31-36 (2012).
7. Moore PB, Huxley HE, Derosier DJ. Three-dimensional reconstruction of F-Actin, thin flaments and decorated thin flaments. J. Mol. Biol. 50(2), 279-295 (1970).
8. Taylor EW. Molecular muscle. Science 261(5117), 35-36 (1993).
9. Margossian SS, Lowey S. Substructure of the myosin molecule. I V. Interactions of myosin and its subfragments with adenosine triphosphate and F-Actin. J. Mol. Biol. 74 (3), 313-330 (1973).
10. Rayment I, Holden HM, Whittaker M et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science 261(5117), 58-65 (1993).
11. Huxley A F, Niedergerke R. Structural changes in muscle during contraction; interference microscopy of living muscle fbers. Nature 173(4412), 971-973 (1954).
12. Holmes KC, Geeves M.A. The structural basis of muscle contraction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355(1396), 419-431 (2000).
13. Margossian SS, Lowey S. Substructure of the myosin molecule. 3. Preparation of single-headed derivatives of myosin. J. Mol. Biol. 74(3), 301-311 (1973).
14. Mornet D, Pantel P, Audemard E, Kassab R. The limited tryptic cleavage of chymotryptic S-1: an approach to the characterization of the actin site in myosin heads. Biochem. Biophys. Res. Commun. 89(3), 925-932 (1979).
15. Rayment I, Rypniewski WR, Schmidt-Base K et al. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261(5117), 50-58 (1993).
16. Tonomura Y, Oosawa F. Molecular mechanism of contraction. Annu. Rev. Biophys. Bioeng. 1, 159-190 (1972).
17. White MY, Cordwell SJ, Mccarron HC et al. Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems. Proteomics 5(5), 1395-1410 (2005).
18. Polewicz D, Cadete VJ, Doroszko A et al. Ischemia induced peroxynitrite dependent modifcations of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. J. Cell. Mol. Med. 15 (5), 1136-1147 (2011).
19. Sawicki G, Leon H, Sawicka J et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112(4), 544-552 (2005).
20. Holmes KC. Muscle proteins-their actions and interactions. Curr. Opin. Struct. Biol. 6(6), 781-789 (1996).
21. Ebashi S, Kodama A. A new protein factor promoting aggregation of tropomyosin. J. Biochem. 58(1), 107-108 (1965).
22. Murakami K, Yumoto F, Ohki SY et al. Structural basis for calcium-regulated relaxation of striated muscles at interaction sites of troponin with actin and tropomyosin. Adv. Exp. Med. Biol. 592, 71-86 (2007).
23. Greaser ML, Gergely J. Reconstitution of troponin activity from three protein components. J. Biol. Chem. 246(13), 4226-4233 (1971).
24. Boussouf SE, Geeves M.A. Tropomyosin and troponin cooperativity on the thin flament. Adv. Exp. Med. Biol. 592, 99-109 (2007).
25. Scruggs SB, Walker LA, Lyu T et al. Partial replacement of cardiac troponin I with a non-phosphorylatable mutant at serines 43/45 attenuates the contractile dysfunction associated with PKCepsilon phosphorylation. J. Mol. Cell. Cardiol. 40(4), 465-473 (2006).
26. Gao CQ, Sawicki G, Suarez-Pinzon WL et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc. Res. 57(2), 426-433 (2003).
27. Wang W, Schulze CJ, Suarez-Pinzon WL et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106(12), 1543-1549 (2002).
28. Gomes AV, Potter JD. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Mol. Cell. Biochem. 263(1-2), 99-114 (2004).
29. Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ. Res. 94(3), 284-295 (2004).
30. Gregorio CC, Granzier H, Sorimachi H, Labeit S. Muscle assembly: a titanic achievement? Curr. Opin. Cell Biol. 11(1), 18-25 (1999).
31. Fukuda N, Granzier HL, Ishiwata S, Kurihara S. Physiological functions of the giant elastic protein titin in mammalian striated muscle. J. Physiol. Sci. 58 (3), 151-159 (2008).
32. Stansfeld WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann. Thorac. Surg. 84(1), 120-125 (2007).
33. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 79(2), 609-634 (1999).
34. Ali MA, Cho WJ, Hudson B et al. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 122(20), 2039-2047 (2010).
35. Wong HY, Tan JY, Lim CC. Abnormal liver function tests in the symptomatic pregnant patient: the local experience in Singapore. Ann. Acad. Med. Singap. 33(2), 204-208 (2004).
36. Tinsley JH, Hunter FA, Childs EW. PKC and MLCK-dependent, cytokine-induced rat coronary endothelial dysfunction. J. Surg. Res. 152(1), 76-83 (2009).
37. Gao Y, Ye LH, Kishi H et al. Myosin light chain kinase as a multifunctional regulatory protein of smooth muscle contraction. IUBMB Life 51(6), 337-344 (2001).
38. Liu X, Shao Q, Dhalla NS. Myosin light chain phosphorylation in cardiac hypertrophy and failure due to myocardial infarction. J. Mol. Cell. Cardiol. 27(12), 2613-2621 (1995).
39. Yuan SY, Wu MH, Ustinova EE et al. Myosin light chain phosphorylation in neutrophil-stimulated coronary microvascular leakage. Circ. Res. 90(11), 1214-1221 (2002).
40. Lin HB, Cadete VJ, Sawicka J, Wozniak M, Sawicki G. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion inju r y. J. Proteomics 75(17), 5386-5395 (2012).
41. Nakanishi S, Yamada K, Kase H, Nakamura S, Nonomura Y. K-252a, a novel microbial product, inhibits smooth muscle myosin light chain kinase. J. Biol. Chem. 263(13), 6215-6219 (1988).
42. Kelley SJ, Thomas R, Dunham PB. Candidate inhibitor of the volume-sensitive kinase regulating K-Cl cotransport: the myosin light chain kinase inhibitor ML-7. J. Membr. Biol. 178(1), 31-41 (2000).
43. Isemura M, Mita T, Satoh K, Narumi K, Motomiya M. Myosin light chain kinase inhibitors ML-7 and ML-9 inhibit mouse lung carcinoma cell attachment to the fbronectin substratum. Cell Biol. Int. Rep. 15(10), 965-972 (1991).
44. Deng M, Williams CJ, Schultz RM. Role of MAP kinase and myosin light chain kinase in chromosome-induced development of mouse egg polarity. Dev. Biol. 278(2), 358-366 (2005).
45. Luh C, Kuhlmann CR, Ackermann B et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J. Neurochem. 112 (4), 1015-1025 (2010).
46. Rosenthal R, Choritz L, Schlott S et al. Effects of ML-7 and Y-27632 on carbachol-And endothelin-1-induced contraction of bovine trabecular meshwork. Exp. Eye Res. 80(6), 837-845 (2005).
47. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J. Biol. Chem. 274 (31), 21491-21494 (1999).
48. Salo T, Makela M, Kylmaniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and-9 during early human wound healing. Lab Invest. 70(2), 176-182 (1994).
49. Mosig RA, Dowling O, Difeo A et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum. Mol. Genet. 16 (9), 1113-1123 (2007).
50. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103(9), 1237-1241 (1999).
51. Chang YH, Lin IL, Tsay GJ et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Biochem. 41(12), 955-959 (2008).
52. Benesova Y, Vasku A, Novotna H et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 15(3), 316-322 (2009).
53. Gokaslan ZL, Chintala SK, York JE et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis 16(8), 721-728 (1998).
54. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89(3), 201-210 (2001).
55. Dollery CM, Mcewan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77(5), 863-868 (1995).
56. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 46(2), 225-238 (2000).
57. Lee RT. Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc. Med. 11(5), 202-205 (2001).
58. Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45(5), 351-423 (2010).
59. Sung MM, Schulz CG, Wang W et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-Actinin in peroxynitrite mediated myocardial injury. J. Mol. Cell. Cardiol. 43(4), 429-436 (2007).
60. Corbel M, Boichot E, Lagente V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J. Med. Biol. Res. 33(7), 749-754 (2000).
61. Han B, Zhao X, Huang X, Xie L. Vaporized perfuorocarbon confers protection against acute lung injury by inhibiting MMP-9 expression without protective effects in other organs. J. Int. Med. Res. 40(1), 115-125 (2012).
62. Doroszko A, Hurst TS, Polewicz D et al. Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung inju r y. Proteome Sci. 8, 3 (2010).
63. St-Pierre Y, Couillard J, Van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and infammatory diseases. Expert Opin. Ther. Targets 8(5), 473-489 (2004).
64. Martens E, Leyssen A, Van Aelst I et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fbronectin or zinc binding domains. Biochim. Biophys. Acta 1770(2), 178-186 (2007).
65. Saglam F, Cavdar Z, Sarioglu S et al. Pioglitazone reduces peritoneal fbrosis via inhibition of TGF-beta, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. Ren. Fail. 34(1), 95-102 (2012).
66. Marchesi C, Dentali F, Nicolini E et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-Analysis. J. Hypertens. 30(1), 3-16 (2012).
67. Zhao S, Choksuchat C, Zhao Y et al. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception 79(6), 469-478 (2009).
68. Overall CM. Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J. 383(Pt 3), e5-e7 (2004).
69. St-Pierre Y, Couillard J, Van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and infammatory diseases. Expert Opin. Ther. Targets 8(5), 473-489 (2004).
70. Ali MA, Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front. Biosci. 14, 699-716 (2009).
71. Viappiani S, Nicolescu AC, Holt A et al. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 77(5), 826-834 (2009).
72. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 53(1), 165-174 (2002).
73. Sariahmetoglu M, Crawford BD, Leon H et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 21(10), 2486-2495 (2007).
74. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversit y. Biochim. Biophys. Acta 1803(1), 55-71 (2010).
75. Falk V, Soccal PM, Grunenfelder J et al. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur. J. Cardiothorac. Surg. 22(1), 53-58 (2002).
76. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69(3), 677-687 (2006).
77. Agren MS, Mirastschijski U, Karlsmark T, Saarialho-Kere UK. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp. Dermatol. 10(5), 337-348 (2001).
78. Cheung PY, Sawicki G, Wozniak M et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101(15), 1833-1839 (2000).
79. Leon H, Baczko I, Sawicki G, Light PE, Schulz R. Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br. J. Pharmacol. 153(4), 676-683 (2008).
80. Fert-Bober J, Leon H, Sawicka J et al. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effuent from isolated rat hearts during ischemia-reperfusion. Basic Res. Cardiol. 103 (5), 431-443 (2008).
81. Golub LM, Lee HM, Ryan ME et al. Tetracyclines inhibit connective tissue breakdown by multiple non-Antimicrobial mechanisms. Adv. Dent. Res. 12(2), 12-26 (1998).
82. Tessone A, Feinberg MS, Barbash IM et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc. Drugs Ther. 19(6), 383-390 (2005).
83. He G. Electron paramagnetic resonance oximetry and redoximetry. Methods Mol. Biol. 594, 85-105 (2010).
84. Sanz-Rosa D, Garcia-Prieto J, Ibanez B. The future: therapy of myocardial protection. Ann. NY Acad. Sci. 1254, 90-98 (2012).
85. Marchant DJ, Boyd JH, Lin DC et al. Infammation in myocardial diseases. Circ. Res. 110(1), 126-144 (2012).
86. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85(3), 1093-1129 (2005).
87. Tucka J, Bennett M, Littlewood T. Cell death and survival signaling in the cardiovascular system. Front. Biosci. 17, 248-261 (2012).
88. Baines CP. How and when do myocytes die during ischemia and reperfusion: the late phase. J. Cardiovasc. Pharmacol. Ther. 16(3-4), 239-243 (2011).
89. Rouet-Benzineb P, Buhler JM, Dreyfus P et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur. J. Heart Fail. 1(4), 337-352 (1999).
90. Sawicki G, Jugdutt BI. Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury: functional proteomics studies. Proteomics 4(7), 2195-2202 (2004).
91. Gu X, Liu X, Xu D et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc. Res. 88(2), 334-343 (2010).
92. Thygesen K, Alpert JS, Jaffe AS et al. Third universal defnition of myocardial infarction. Eur. Heart J. 33(20), 2551-2567 (2012).
93. Seguchi O, Takashima S, Yamazaki S et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J. Clin. Invest. 117(10), 2812-2824 (2007).